| SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and-independent mechanisms S Osataphan, C Macchi, G Singhal, J Chimene-Weiss, V Sales, C Kozuka, ... JCI insight 4 (5), 2019 | 139 | 2019 |
| Clinical inertia causing new or progression of diabetic retinopathy in type 2 diabetes: A retrospective cohort study: 临床惰性可导致 2 型糖尿病患者新发视网膜病变或视网膜病变进 … S Osataphan, T Chalermchai, K Ngaosuwan Journal of Diabetes 9 (3), 267-274, 2017 | 43 | 2017 |
| Prevalence of thyroid diseases in familial adenomatous polyposis: a systematic review and meta-analysis J Chenbhanich, A Atsawarungruangkit, S Korpaisarn, T Phupitakphol, ... Familial Cancer 18, 53-62, 2019 | 17 | 2019 |
| Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis S Osataphan, R Patell, T Chiasakul, AA Khorana, JI Zwicker Blood Advances 5 (8), 2055-2062, 2021 | 12 | 2021 |
| Obesity and cholangiocarcinoma: A review of epidemiological and molecular associations S Osataphan, T Mahankasuwan, C Saengboonmee Journal of Hepato‐Biliary‐Pancreatic Sciences 28 (12), 1047-1059, 2021 | 7 | 2021 |
| Bromodomain inhibition reveals FGF15/19 as a target of epigenetic regulation and metabolic control C Kozuka, V Efthymiou, VM Sales, L Zhou, S Osataphan, Y Yuchi, ... Diabetes 71 (5), 1023-1033, 2022 | 4 | 2022 |
| Trim the gut, lose the weight—and the bone S Osataphan, ME Patti The Journal of Clinical Investigation 129 (6), 2184-2186, 2019 | 3 | 2019 |
| Diabetes Mellitus Treated with Medical Nutritional Therapy and Self Blood Glucose Monitoring: A Randomized Controlled Trial. K Ngaosuwan, S Osataphan Journal of the Medical Association of Thailand= Chotmaihet Thangphaet 98, S66-73, 2015 | 3 | 2015 |
| Triple-hit high-grade B-cell lymphoma presenting with ovarian torsion S Osataphan, A Augustynowicz, C Perrino, P Lam BMJ Case Reports CP 14 (5), e242423, 2021 | 1 | 2021 |
| Anti-Insulin Receptor Antibody for Malignant Insulinoma and Refractory Hypoglycemia S Osataphan, M Vamvini, ED Rosen, L Pei, N Erlikh, G Singh, P Dhorajiya, ... The New England journal of medicine 389 (8), 767-769, 2023 | | 2023 |
| 1557-P: Ctcfl Is a Fasting-Induced Epigenetic Regulator of Lipid Metabolism and Ketogenesis in the Liver V EFTHYMIOU, L POULOS, L STRAUB, V NAVARRETE, B OZTURK, ... Diabetes 72 (Supplement_1), 2023 | | 2023 |
| Obesity, dyslipidemia, and diabetes as determinants of response to immune checkpoint inhibitors in non-small cell lung cancer. SA Osataphan, M Awidi, YJ Jan, S Sundararaman, H Viray, ... Journal of Clinical Oncology 41 (16_suppl), e21125-e21125, 2023 | | 2023 |
| ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor–Responsive Lung Cancer Driver Oncogene ZR Schoepflin, E Academia, SA Osataphan, D Rangachari, S Sharifi, ... JTO Clinical and Research Reports 4 (4), 100489, 2023 | | 2023 |
| Obesity diabetes and dyslipidemia as determinants of immune checkpoint inhibitors response in non-small cell lung cancer. M Awidi, S Osataphan, YJ Jan, E Frankenberger, M Mariano, KA Stafford, ... Journal of Clinical Oncology 40 (16_suppl), e21104-e21104, 2022 | | 2022 |
| 280-OR: CTCFL Is a Fasting-Induced Epigenetic Regulator That Modulates Lipid and Cholesterol Metabolism in the Liver V Efthymiou, JI Chimene-Weiss, L Zhou, S Osataphan, L Su, ME Patti Diabetes 70 (Supplement_1), 2021 | | 2021 |
| Effect of excess weight on immune-related adverse events from immune checkpoint inhibitor in lung cancer. S Osataphan, YJ Jan, KA Stafford, PB Lam Journal of Clinical Oncology 39 (15_suppl), e21183-e21183, 2021 | | 2021 |
| Paternal Obesity and SGLT2 Inhibition Alter Expression of Placental Regulatory Genes L Su, S Osataphan, J Desmond, R Fang, J Chimene-Weiss, L Zhou, ... Journal of the Endocrine Society 5 (Supplement_1), A752-A753, 2021 | | 2021 |
| 373-OR: Paternal SGLT2 Inhibition Upregulates Hepatic Expression of Oxidative Phosphorylation Genes in Both Fetal and Adult Offspring L Su, S Osataphan, C Macchi, JI Chimene-Weiss, J Dreyfuss, H Pan, ... Diabetes 69 (Supplement_1), 2020 | | 2020 |
Mary Elizabeth PattiInvestigator, Joslin Diabetes Center; Associate Professor, Harvard Medical School在 joslin.harvard.edu 的电子邮件经过验证
Mary Elizabeth PattiInvestigator, Joslin Diabetes Center; Associate Professor, Harvard Medical School在 joslin.harvard.edu 的电子邮件经过验证